TABLE 5.

Comparison of outcomes between CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)‐25 and CHOP‐19 protocols in dogs with peripheral nodal B‐cell lymphomas (PNBCL).

Variable	CHOP‐19	CHOP‐25	P‐value
ORR	141/145 (97.2%, 95% CI, 94.6%‐99.9%)	322/337 (95.5%, 95% CI, 93.3%‐97.8%)	.54
CR	117/145 (80.7%, 95% CI, 74.3%‐87.1%)	276/337 (81.9%, 95% CI, 77.8%‐86%)	.85
6‐month PFS	56.5% (95% CI, 49.2‐65)	56.4% (95% CI, 51.4‐61.9)	.98
1‐year PFS	14.1% (95% CI, 9.4‐21)	17% (95% CI, 13.4‐21.6)	.41
PFS	196 (95% CI, 176‐233)	209 (95% CI, 187‐224)	.22
1‐year OS	36.9% (95% CI, 29.7‐46)	42.8% (95% CI, 37.7‐48.7)	.24
2‐year OS	13.5% (95% CI, 8.6‐21.1)	15.4% (95% CI, 11.7‐20.4)	.61
OS	302 (95% CI, 249‐338)	321 (95% CI, 293‐357)	.61

Abbreviations: CI, confidence interval; CR, complete response; PFS, progression‐free survival; PNBCL, peripheral nodal B‐cell lymphoma; ORR, overall response rate; OS, overall survival.